 |
|
Multiple-Dose Arecoline Infusions in Alzheimer's Disease
Pierre N. Tariot, MD;
Robert M. Cohen, MD, PhD;
Julie A. Welkowitz;
Trey Sunderland, MD;
Paul A. Newhouse, MD;
Dennis L. Murphy, MD;
Herbert Weingartner, PhD
Arch Gen Psychiatry. 1988;45(10):901-905.
Abstract
• Twelve patients with dementia of the Alzheimer type received two-hour infusions of placebo and the muscarinic cholinergic agonist arecoline hydrobromide at rates of 1,2, and 4 mg/h in a double-blind, randomized fashion. These infusions resulted in dose-dependent physiologic and neuroendocrine effects consistent with central cholinergic stimulation. Infusions were generally well tolerated. No statistically significant improvement in performance on most cognitive tasks assessing knowledge memory and episodic learning and memory was observed at any dose, although marginal improvement in picture recognition ability and in ratings of word-finding were observed at the lower doses. Psychomotor activation and slightly improved affect were reliably observed at the lower doses, whereas increasing psychomotor retardation was observed at the highest dose. The data support a role for central cholinergic modulation of some aspects of cognition, behavior, and affect in this population. The apparent greater behavioral sensitivity of patients with Alzheimer's disease in comparison with subject populations previously studied, as well as the altered dose responsiveness, merit further study in relationship to normal aging.
Author Affiliations
From the Laboratories of Clinical Science (Drs Tariot, Sunderland, Newhouse, and Murphy) and Cerebral Metabolism (Dr Cohen), National Institute of Mental Health, the Department of Behavioral Biology, Division of Neuropsychiatry, Walter Reed Army Institute of Research (Dr Newhouse), and the Psychology Department, George Washington University (Dr Weingartner), Washington, DC; the Psychiatry Unit, Monroe Community Hospital, University of Rochester (NY) School of Medicine (Dr Tariot); and the Psychology Department, University of Vermont, Burlington (Ms Welkowitz).
Footnotes
Accepted for publication Aug 26, 1987.
Reprint requests to Psychiatry Unit, Monroe Community Hospital, University of Rochester School of Medicine, 435 E Henrietta Rd, Rochester, NY 14603 (Dr Tariot).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease
Thal et al.
Neurology 2000;54:421-421.
ABSTRACT
| FULL TEXT
Do We Have Drugs for Dementia?: No
Pryse-Phillips
Arch Neurol 1999;56:735-737.
FULL TEXT
SB 202026: A Novel Muscarinic Partial Agonist with Functional Selectivity for M1 Receptors
Loudon et al.
J. Pharmacol. Exp. Ther. 1997;283:1059-1068.
ABSTRACT
| FULL TEXT
Pharmacotherapy of Cognitive Impairment in Alzheimer's Disease: A Review
Patel
J Geriatr Psychiatry Neurol 1995;8:81-95.
ABSTRACT
The treatment of Alzheimer's disease
Allen and Burns
J Psychopharmacol 1995;9:43-56.
Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial
Maltby et al.
BMJ 1994;308:879-883.
ABSTRACT
| FULL TEXT
Drug Treatment of Alzheimer's Disease
Cooper
Arch Intern Med 1991;151:245-249.
ABSTRACT
|
